Healthcare Industry News: HSMN NewsFeed
News Release - December 7, 2017
Bioness StimRouter(R) Neuromodulation System Eligible for Increased Medicare ReimbursementsMedicare patients suffering from chronic peripheral nerve pain will have greater access to treatment starting January 1, 2018
VALENCIA, Calif., Dec. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Bioness, Inc., the leading provider of cutting edge, clinically supported rehabilitation therapies, is pleased to announce that the Centers for Medicare & Medicaid Service (CMS) has approved significantly larger payment rates for the StimRouter® Neuromodulation System in the Hospital Outpatient Prospective Payment System (HOPPS), under Current Procedural Terminology (CPT®) code, 64555, for percutaneous implantation of a neurostimulator electrode array. Effective January 1, 2018, providers will receive increased payments from Medicare for the StimRouter® implant procedure, making the device an even more viable pain management option for patients and physicians nationwide.
StimRouter is a minimally-invasive implanted device that is clinically proven to reduce pain by delivering gentle electrical pulses to stimulate the affected peripheral nerve which essentially 'blocks' pain signals before they reach the brain. It is a cost-effective, long-term use alternative to prescribed opioids, injections, and mobility therapies. "Many patients suffering from chronic pain are looking for effective alternatives to prescription medications and other traditional therapies which typically only offer short term solutions to the long-term problem of debilitating chronic pain," said Todd Cushman, president and CEO of Bioness. "With the new payment ruling from CMS, we expect StimRouter will become widely available, allowing more patients to benefit from extended pain relief using our physician-implanted device with wireless controller that allows individuals to assume control over their pain."
Under the new HOPPS rule, the payment rate for CPT code 64555 will increase by 11% when the StimRouter implantation procedure is performed in an outpatient hospital and 3% when the procedure is performed in an ambulatory surgery center. Additionally, CMS' 2018 Medicare Physician Fee Schedule (MPFS) increases reimbursement by 124% when the StimRouter implant procedure is performed in a physician's office.
StimRouter is the first FDA-cleared neuromodulation device indicated to treat chronic pain of peripheral nerve origin. The medical device is being implanted at clinical institutions across the United States.
For more information about StimRouter and its indication for use, visit the website here.
About StimRouter® Neuromodulation System
StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients' specific, changing pain management needs.
About Bioness, Inc.
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Our technologies have been implemented in the most prestigious and well-respected institutions around the globe with approximately 90% of the top rehabilitation hospitals in the United States currently using one or more Bioness solution. Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBioness Receives FDA Clearance for myBioness(TM) iOS app for mobile control of the L300 Go(TM) System
New Medical Policy Makes the Bioness StimRouter(R) Neuromodulation System a Covered Benefit for Highmark Blue Cross Blue Shield Policy Holders
Bioness Receives Health Canada Approval for StimRouter Neuromodulation System